Another CAR-T First: Yescarta Wins Lymphoma Funding In England

 
• By Ian Schofield

Gilead has agreed a confidential deal with NHS England under which its pioneering CAR-T therapy Yescarta will be provided to adult lymphoma patients under the Cancer Drugs Fund. The funding decision gives Yescarta an edge in the lymphoma market over Kymriah, the other EU-authorized CAR-T treatment.

Chimeric antigen receptor
Yescarta helps the body's T cells attack cancer • Source: Shutterstock

More from Market Access

More from Pink Sheet